glp-1 receptor agonist for weight loss GLP1 Agonists—Effects beyond Obesity and Diabetes Glucagon-like peptide-1 receptor agonists (GLP-1RAs)

Chromium picolinate is sometimes marketed for blood sugar support, though evidence for direct effects on GLP-1 or GIP is minimal

N Engl J Med (2021) 385:896907

3.4 Physical activity recommendations in patients with obesity on GLP-1RAs Patients receiving GLP-1RAs experience significant weight loss but are also at increased risk of lean body mass and bone density loss

Where there is limited evidence, physicians are relying on their training and clinical knowledge to guide them

Breast cancer remains the most common cancer among women in the USA, apart from skin cancer, and accounts for nearly one third of all female cancer cases

As with any medicine, there is a possibility of unwanted effects